Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.
Eur Heart J. 2011 Dec;32(23):2922-32. doi: 10.1093/eurheartj/ehr373. Epub 2011 Oct 20.
The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.
抗血小板药物的临床药理学先前已由欧洲心脏病学会（ESC）工作组和第 8 版美国胸科医师学会（ACCP）循证临床实践指南进行了审查。此外，关于抗血小板药物在治疗和预防动脉血栓形成中的疗效和安全性的信息，来自 287 项二级预防试验和 6 项一级预防试验的协作荟萃分析。本文件旨在为执业医师提供一种更新的工具，以指导他们为有发生动脉血栓形成风险或具有不同临床表现的个体患者选择最合适的抗血小板策略。
